DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02336659

CompletedPhase NA

Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

12

actual

Study population

Bariatric Surgery

Key I/E criterion

—

Primary endpoint

•Ad libitum food intake

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02336659
Org study IDMSV-14

Timeline

Milestones

Study first posted2015-01-13estimated
Last update posted2016-06-21estimated
Study start2014-04 (month precision)
Primary completion2016-05actual (month precision)
Study completion2016-06actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Bariatric Surgery

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Uncomplicated RYGB performed 3-12 month proir to the study. Fasting plasma glucose <7.0 mM and HbA1c < 48 mmol/mol 3 month after RYGB.

Exclusion criteria

•Fasting plasma glucose >7.0 mM and HbA1c > 48 mmol/mol 3 month after RYGB. Hemoglobin <6.5mM. Previous anaphylaxis when treated with Januvia or Byetta. Allergy for sitagliptin. Dysregulated hypothyroidism. Use of antithyroid treatment. Late diabetic complications as retinopathy, renal insuffiency, neuropathy or previous pancreatitis. Bad compliance.
•Complications to RYGB: Documented reactive hypoglycaemia, severe dumping (with vomiting, diarrhea or severe abdominal pain after food intake).

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Patient-reported / QoL
1
Other clinical outcomes
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Glucose metabolism (iAUC of glucose and c-pep after a meal)

Time frame:3-12 month after RYGB

C-peptide AUC

descriptive

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Appetite measurement (VAS-scores)

Time frame:3-12 month after RYGB

descriptive

Other clinical outcomes

1 endpoint
Primary/protocol endpoint/low confidence

Ad libitum food intake (changes in food intake)

Time frame:3-12 month after RYGB

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Gut-derived hormone profiles (iAUC of GLP-1, PYY, GIP and glucagon after a meal)

Time frame:3-12 month after RYGB

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.